No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.

• Tasly Pharmaceutical Group Co., Ltd
• Sumitomo Pharma Co., Ltd.
• Hanmi Pharm. Co., Ltd.
• Hubei Jumpcan Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.
• China Medical System Holdings Limited
• Guangdong Zhongsheng Pharmaceutical Co., Ltd.
• Laboratorios Farmaceuticos Rovi, S.A.